p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression

Ivano Amelio(University of Cambridge), Mara Mancini(Istituto Dermopatico dell'Immacolata), Varvara Petrova(University of Cambridge), Rob A. Cairns(University Health Network), П. Н. Вихрева(University of Cambridge), Sara Nicolai(University of Cambridge), Alberto Marini(University of Cambridge), А. Антонов(University of Cambridge), John Le Quesne(University of Leicester), Juvenal Dario Baena Acevedo(University of Leicester), Kate Dudek(University of Cambridge), Gabriella Sozzi(Fondazione IRCCS Istituto Nazionale dei Tumori), Ugo Pastorino(Fondazione IRCCS Istituto Nazionale dei Tumori), Richard A. Knight(University of Cambridge), Tak W. Mak(University Health Network), Gerry Melino(University of Rome Tor Vergata)
Proceedings of the National Academy of Sciences
October 31, 2018
Cited by 136Open Access
Full Text

Abstract

gene and microenvironmentally driven activation of hypoxia-inducible factor-1 (HIF-1) typically occur in later stages of tumorigenesis. An ongoing challenge is the identification of molecular determinants of advanced cancer pathogenesis to design alternative last-line therapeutic options. Here, we report that p53 mutants influence the tumor microenvironment by cooperating with HIF-1 to promote cancer progression. We demonstrate that in non-small cell lung cancer (NSCLC), p53 mutants exert a gain-of-function (GOF) effect on HIF-1, thus regulating a selective gene expression signature involved in protumorigenic functions. Hypoxia-mediated activation of HIF-1 leads to the formation of a p53 mutant/HIF-1 complex that physically binds the SWI/SNF chromatin remodeling complex, promoting expression of a selective subset of hypoxia-responsive genes. Depletion of p53 mutants impairs the HIF-mediated up-regulation of extracellular matrix (ECM) components, including type VIIa1 collagen and laminin-γ2, thus affecting tumorigenic potential of NSCLC cells in vitro and in mouse models in vivo. Analysis of surgically resected human NSCLC revealed that expression of this ECM gene signature was highly correlated with hypoxic tumors exclusively in patients carrying p53 mutations and was associated with poor prognosis. Our data reveal a GOF effect of p53 mutants in hypoxic tumors and suggest synergistic activities of p53 and HIF-1. These findings have important implications for cancer progression and might provide innovative last-line treatment options for advanced NSCLC.


Related Papers

No related papers found

Powered by citation graph analysis